Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY61.45 CNY
Change Today +1.14 / 1.89%
Volume 19.4M
600276 On Other Exchanges
As of 2:15 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

jiangsu hengrui medicine c-a (600276) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/26/15 - CNY61.52
52 Week Low
07/28/14 - CNY29.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JIANGSU HENGRUI MEDICINE C-A (600276)

Related News

No related news articles were found.

jiangsu hengrui medicine c-a (600276) Related Businessweek News

No Related Businessweek News Found

jiangsu hengrui medicine c-a (600276) Details

Jiangsu Hengrui Medicine Co., Ltd. researches, manufactures, and sells pharmaceutical products in China. It offers antineoplastic, angiomyocardiac, antibiotic, and other drugs, as well as APIs in the form of tablets, injectables, injections, oral solutions, capsules, and ointments. The company was founded in 1970 and is headquartered in Lianyungang, China.

Founded in 1970

jiangsu hengrui medicine c-a (600276) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangsu hengrui medicine c-a (600276) Key Developments

Hengrui to Collaborate With MabSpace on Novel Antibody Therapeutics

MabSpace Biosciences Co., Ltd. announced that it has signed a collaborative contract with Jiangsu Hengrui Medicine Co., Ltd, to co-develop novel antibody therapeutics on two targets. According to the agreement, MabSpace will be responsible for the discovery and selection of humanized lead antibodies, while Hengrui will get exclusive global rights on the resulting therapeutic candidates for the nominated targets, and will further develop the selected candidate molecules.

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, May 05, 2015

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, May 05, 2015. Agenda: To discuss and approve the proposal of nominating members of special committees of directorate.

Jiangsu Hengrui Medicine Co., Ltd. Announces Earnings Results for the First Quarter of 2015

Jiangsu Hengrui Medicine Co., Ltd. announced earnings results for the first quarter of 2015. The company revealed operating revenue of CNY 2.204 billion in the first quarter of 2015, rising 28.03% from a year earlier. Net profit attributable to shareholders reached CNY 547 million, hiking 40.23%. Basic EPS were CNY 0.36.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600276:CH CNY61.45 CNY +1.14

600276 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600276.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600276 Industry Range
Price/Earnings 54.1x
Price/Sales 11.4x
Price/Book 10.7x
Price/Cash Flow 54.3x
TEV/Sales 10.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGSU HENGRUI MEDICINE C-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at